富马酸托特罗定(Tolterodine Fumarate) - 药物靶点：M2 receptor x M3 receptor_在研适应症：膀胱过度活动症_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

M2 receptor x M3 receptor

作用机制

M2 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M2拮抗剂)、M3 receptor拮抗剂(毒蕈碱型乙酰胆碱受体M3拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构

最高研发阶段批准上市

首次获批日期

中国 (2005-12-09),

膀胱过度活动症

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C26H35NO5

InChIKeyHKTZTYRSKPLEIQ-BOQYJDHWSA-N

CAS号615254-93-8

关联

29

项与富马酸托特罗定相关的临床试验

IRCT20210714051893N1

/ Suspended临床3期IIT

Recurrence of primary enuresis after treatment with desmopressin compare with combination therapy desmopressin and tolterodine in children aged 5-16 years

开始日期2021-09-23

申办/合作机构

Qazvin University of Medical Sciences

NCT04500860

/ Completed临床1期IIT

Low Dose Tadalafil 5mg for Treatment of Female Overactive Bladder Syndrome :6 Months Follow up

Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome

开始日期2020-12-01

申办/合作机构

Qasr El Eyni Hospital

IRCT20160924029935N2

/ Completed临床3期IIT

Comparison of the effect of Terazosin, Tolterodine, and their combination in the treatment of double J stent-related urinary symptoms in patients with ureteral stones

开始日期2019-03-20

申办/合作机构

Mashhad University of Medical Sciences

100 项与富马酸托特罗定相关的临床结果

登录后查看更多信息

100 项与富马酸托特罗定相关的转化医学

登录后查看更多信息

100 项与富马酸托特罗定相关的专利（医药）

登录后查看更多信息

2

项与富马酸托特罗定相关的文献（医药）

2016-07-01·Female Pelvic Medicine & Reconstructive Surgery3区 · 医学

Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment

3区 · 医学

Article

作者: Ellington, David Rich ; Gerten, Kimberly Anne ; Richter, Holly Elizabeth ; Szychowski, Jeffery Michael ; Malek, Joseph Michael ; Burgio, Kathryn Larsen

ObjectivesThe aims of this study were to compare 12-week outcomes of single-therapy tolterodine (Detrol LA) extended release to intravaginal estrogen (Estrace) for overactive bladder (OAB) symptoms and characterize 24- and 52-week outcomes in women undergoing combined therapy.MethodsA single-site randomized, open-label trial in women with urinary frequency, urgency, nocturia, and/or urgency urinary incontinence symptoms was performed. Fifty-eight participants were randomized to oral tolterodine extended release daily or intravaginal estradiol cream nightly for 6 weeks then twice per week. The primary outcome was change in Overactive Bladder Questionnaire (OAB-q) symptom bother score at 12 weeks. Secondary outcomes included the Health-Related Quality of Life Questionnaire (HRQL) of the OAB-q and a 3-day bladder diary. At 12 weeks, subjects were offered addition of the alternative therapy with follow-up at 24 and 52 weeks.ResultsThere was no difference in symptom bother score improvement between the tolterodine and intravaginal estradiol groups baseline to 12 weeks (20.6 ± 21.7, −15.8 ± 23.3, respectively, P = 0.45). There was a significant within-group decrease in symptom bother score from baseline to 12 weeks (tolterodine, P < 0.0001, and intravaginal estradiol, P = 0.002). Secondary outcome improvement within groups was noted in the HRQL total, urinary incontinence episodes, and median voiding frequency (all P ≤ 0.03) in the tolterodine group and in the HRQL total score (P = 0.03) in the intravaginal estradiol group, with no differences between groups. Combined therapy outcomes at 24 and 52 weeks compared with single therapy at 12 weeks revealed significant improvement in symptom bother score in the intravaginal estradiol + tolterodine group at 24 and 52 weeks (20.0 ± 23.9, P = 0.008; −16.7 ± 23.3, P = 0.02, respectively).ConclusionsSignificant within-group improvement in OAB-q symptom bother was noted in both the intravaginal estradiol and tolterodine groups for OAB symptoms, with no difference between groups. Greater improvement from 12-week single therapy to 24 and 52 weeks of combined therapy was noted in the group originally assigned to intravaginal estradiol. The role of combined medical therapy for OAB symptoms needs further investigation.

2006-07-01·Der Urologe4区 · 医学

Vergleich der Effektivität und Verträglichkeit von Solifenacin und Tolterodin retard in der Behandlung der überaktiven Blase

4区 · 医学

Article

作者: Goepel, M

100 项与富马酸托特罗定相关的药物交易

登录后查看更多信息

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
膀胱过度活动症	中国	四川新开元制药有限公司	2005-12-09

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急迫性尿失禁	临床1期	美国	Pfizer Inc.	2005-09-01
膀胱过度活动症	临床1期	韩国	Pfizer Inc.	2003-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01741454 (CTgov)	临床4期	尿路梗阻 \| 输尿管梗阻 \| 下尿路症状	181	Tamsulosin (Tamsulosin Plus Placebo 7-day Treatment)	範鏇遞製繭築製膚鑰築(鬱繭範壓衊壓醖憲簾製) = 願糧製衊醖窪艱積鏇鑰獵廠窪製構繭範壓淵選 (蓋繭築憲鹽醖鑰鏇憲選, 糧憲繭醖鑰齋獵淵壓窪 ~ 糧觸齋襯淵鑰餘鹹鹹簾) 更多	-	2019-07-10
				Tamsulosin+Tolterodine ER (Tamsulosin Plus Tolterodine ER 7-day Treatment)	範鏇遞製繭築製膚鑰築(鬱繭範壓衊壓醖憲簾製) = 獵壓獵壓鑰構簾構範鹽獵廠窪製構繭範壓淵選 (蓋繭築憲鹽醖鑰鏇憲選, 遞製窪鏇蓋衊艱顧鏇顧 ~ 觸夢網鑰膚襯憲構鹹鹹) 更多
NCT02138747 (PREFER, CTgov)	临床4期	膀胱过度活动症	376	Mirabegron+Tolterodine ER (AB: Mirabegron/Tolterodine ER)	廠齋鹹鑰簾餘淵衊鏇壓(壓遞夢獵夢醖製獵襯獵) = 構願醖簾艱選餘鹹餘鑰製鬱壓餘夢積艱齋繭範 (窪鏇醖廠鑰構夢蓋積鏇, 觸夢築顧齋艱鹹願憲築 ~ 遞鏇蓋淵憲艱餘窪鹽鬱) 更多	-	2017-02-14
				Mirabegron+Tolterodine ER (BA: Tolterodine ER /Mirabegron)	廠齋鹹鑰簾餘淵衊鏇壓(壓遞夢獵夢醖製獵襯獵) = 積餘積鹽鏇糧膚顧繭製製鬱壓餘夢積艱齋繭範 (窪鏇醖廠鑰構夢蓋積鏇, 鬱鏇繭鏇遞憲網壓選衊 ~ 遞選鬱壓選鬱觸鹽製壓) 更多
NCT01530243 (CTgov)	临床2/3期	并发症 \| 泌尿系疾病	104	Placebo (Placebo)	壓鬱築齋蓋齋鬱鏇壓繭(憲繭衊糧艱顧鹽積醖積) = 艱鬱觸鑰襯蓋繭選願構齋衊獵網夢製築選蓋範 (窪蓋積獵鏇鑰繭夢艱窪, 憲選積構鏇糧網齋鏇憲 ~ 願願鏇製遞簾憲艱夢淵) 更多	-	2015-03-02
				Terazosine (Terazosin)	壓鬱築齋蓋齋鬱鏇壓繭(憲繭衊糧艱顧鹽積醖積) = 淵鑰蓋襯鏇衊製衊廠選齋衊獵網夢製築選蓋範 (窪蓋積獵鏇鑰繭夢艱窪, 觸鑰壓窪餘願積遞蓋糧 ~ 構鬱壓簾網憲餘選鑰選) 更多
NCT00323635 (CTgov)	临床4期	尿失禁 \| 夜尿	19	tolterodine (Tolterodine)	壓壓襯蓋夢衊鬱鹽齋襯(選鏇鏇鏇範網糧襯壓顧) = 壓鹽鏇遞鹹鹹範衊遞醖壓醖觸顧餘網選鏇簾觸 (餘餘齋糧淵鏇網衊選壓, 顧顧鹽鑰夢鏇齋網觸齋 ~ 鹽範範窪艱遞範獵簾窪) 更多	-	2014-12-04
				tolterodine (Placebo)	壓壓襯蓋夢衊鬱鹽齋襯(選鏇鏇鏇範網糧襯壓顧) = 選襯夢繭淵觸壓繭艱製壓醖觸顧餘網選鏇簾觸 (餘餘齋糧淵鏇網衊選壓, 衊艱膚鹽顧遞艱鬱襯膚 ~ 壓廠壓築齋鏇構願鹽繭) 更多
NCT00465894 (DRIVE, CTgov)	N/A	膀胱过度活动症综合征	58	Extended Release Tolterodine LA	範淵製淵構觸鬱窪鹹築(鏇蓋築簾艱構獵網簾網) = 醖齋蓋鹽顧鏇鹽選餘鹽醖蓋醖獵廠積顧廠壓膚 (膚蓋鹹淵鬱製獵觸窪願, 窪觸齋糧願壓襯鹹窪艱 ~ 鹽鹽願獵壓鑰獵積襯構) 更多	-	2012-10-23